PHARMACOKINETICS AND TISSUE RESIDUES OF NORFLOXACIN AND ITS N-DESETHYL-METABOLITES AND ORE-METABOLITES IN HEALTHY PIGS

被引:16
作者
ANADON, A
MARTINEZLARRANAGA, MR
DIAZ, MJ
FERNANDEZ, R
MARTINEZ, MA
FERNANDEZ, MC
机构
[1] Institute of Pharmacology and Toxicology, Csic, Department of Toxicology, Faculty of Veterinary Medicine, Universidad Complutense de Madrid, Madrid
关键词
D O I
10.1111/j.1365-2885.1995.tb00582.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetic properties of norfloxacin were determined in healthy pigs after single intramuscular (i.m.) and intravenous (i.v.) dosage of 8 mg/kg body weight. After i.m. and i.v. administration, the plasma concentration-time graph was characteristic of a two-compartment open model. After single i.m. administration, norfloxacin was absorbed rapidly, with a t(max) of 1.46 +/- 0.06 h. The elimination half-life (t(1/2 beta)) and the mean residence time of norfloxacin in plasma were 4.99 +/- 0.28 and 6.05 +/- 0.22 h, respectively, after i.m. administration and 3.65 +/- 0.16 and 3.34 +/- 0.16 h, respectively, after i.v. administration. Intramuscular bioavailability was found to be 53.7 +/- 4.4%. Plasma concentrations greater than 0.2 mu g/mL were achieved at 20 min and persisted up to 8 h post-administration. Maximal plasma concentration was 1.11 +/- 0.03 mu g/mL. statistically significant differences between the two routes of administration were found for the half-lives of both distribution and elimination phases(t(1/2 alpha), t(1/2 beta)) and apparent volume of distribution (V-d(area)). In pigs, norfloxacin was mainly converted to desethylenenorfloxacin and oxonorfloxacin, Considerable tissue concentrations of norfloxacin, desethylenenorfloxacin, and oxonorfloxacin were found when norfloxacin was administered intramuscularly (8 mg/kg on 4 consecutive days). The concentration of the parent fluoroquinolone in liver and kidney ranged between 0.015 and 0.017 mu g/g on day 12 after the end of dosing.
引用
收藏
页码:220 / 225
页数:6
相关论文
共 31 条
[11]  
Hannan P.C.T., Treatment of experimental enzootic pneumonia of the pig by norfloxacin or its 6‐chloro analogue, Research in Veterinary Science, 49, pp. 203-210, (1990)
[12]  
Hannan P.C.T., O'Hanlon P.J., Rogers N.H., In vitro evaluation of various quinolone antibacterial agents against veterinary mycoplasmas and porcine respiratory bacterial pathogens, Research In Veterinary Science, 46, pp. 202-211, (1989)
[13]  
Holmes B., Brogden R.N., Richards D.M., Norfloxacin, a review of its antibacterial activity, pharmacokinetic properties and therapeutic use, Drugs, 30, pp. 482-513, (1985)
[14]  
Ito A., Hirai K., Inoue M., Koga K, Susue S., Irikura T., In vitro antibacterial activity of AM‐715, a new nalidixic add analog, Antimicrobial Agents and Chemotherapy, 17, pp. 103-108, (1980)
[15]  
Khan M.Y., Gruninger R.P., Nelson S.M., Klicker R.E., Comparative in vitro activity of norfloxacin (MK‐0366) and ten other oral antimicrobial agents against urinary bacterial isolates, Antimicrobial Agents and Chemotherapy, 21, pp. 848-851, (1982)
[16]  
Neu H.C., Labthavikul P., In vitro activity of norfloxacin, a quinolinecarboxilic acid, compared with that β‐lactams, aminoglycosides, and trimethoprim, Antimicrobial Agents and Chemotherapy, 22, pp. 23-27, (1982)
[17]  
Newsom S.W.B., The antimicrobial spectrum of norfloxacin, Journal of Antimicrobial Chemotherapy, 13, pp. 25-31, (1984)
[18]  
Norrby S.R., Jonsson M., Antibacterial activity of norfloxacin, Antimicrobial Agents and Chemotherapy, 23, pp. 15-18, (1983)
[19]  
Ozaki T., Uchida H., Alrikura T., Studies on metabolism of AM‐715 in humans by high performance liquid chromatography, Chemotherapy, 4, pp. 128-135, (1981)
[20]  
Pijpers A., Noordhuizen-Stassen E.N., Goedegebuure S.A., Verheijden J.H.M., Intravenous catheterization of conventional pigs without application of antimicrobial agents, Veterinary Quarterly, 11, pp. 216-221, (1989)